BSE - Delayed Quote INR

Lupin Limited (LUPIN.BO)

1,580.05 -0.50 (-0.03%)
At close: April 24 at 3:29 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Ms. Vinita D. Gupta CEO & Executive Director 109.2M -- 1968
Mr. Ramesh Swaminathan Global CFO, CRO, Head of Corporate Affairs & Executive Director 66.86M -- 1966
Mr. Nilesh Deshbandhu Gupta MD & Executive Director 49.6M -- --
Mr. Johnny Mack Mikell President & Global Head of Quality -- -- --
Mr. Christoph Funke Chief Technical Operations Officer -- -- --
Mr. Sreeji Gopinathan Chief Information Officer -- -- --
Dr. Shahin Fesharaki Global Chief Scientific Officer -- -- --
Dr. Hemant Bakhru Vice President of Investor Relations and M&A -- -- --
Dr. Sofia Mumtaz President of Legal and Compliance of Australia, Japan & Canada Business -- -- --
Ms. Diana Amador-Toro Senior Vice President of Global Compliance -- -- --

Lupin Limited

Kalpataru Inspire
3rd Floor Off. Western Expressway Highway Santacruz (East)
Mumbai, 400055
India
91 22 6640 2323 https://www.lupin.com
Sector: 
Healthcare
Full Time Employees: 
20,933

Description

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Corporate Governance

Lupin Limited’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 1; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jul 14, 2023
    Ex-Dividend Date

Upcoming Events

May 06, 2024
Lupin Limited Earnings Call

Related Tickers